Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Rightmove still overvalued with another REA bid unlikely, says Jefferies

(Sharecast News) - The market continues to overvalue Rightmove, with the shares pricing in another takeover offer from REA Group that's unlikely to materialise, according to Jefferies, which reiterated an 'underperform' stance on the stock. The broker, which cut its rating from 'hold' just last month, said "recent news flow supports our view".

Australian real estate information giant CoStar is continuing to make moves in the UK through its OnTheMarket business, while real estate sentiment towards Rightmove is continuing to sour - as evidenced by a recent petition for a CMA investigation into pricing practices at the firm.

"At the time of writing, signatories to the petition total 1,359 (vs an independent agency base of c.15k)," Jefferies said. And while the broker acknowledged that the petition is unlikely to succeed in getting the CMA to intervene, exasperated agents could look to switch to new providers as competition picks up.

Meanwhile, last week's speculation that CoStar is interested in buying Australia's number-two property marketplace Domain - second only to REA, which was rebuffed in a takeover attempt of Rightmove last year - means that REA is unlikely to attempt another takeover of the UK company, Jefferies said.

"Alongside the risk that REA now faces with a potential new entrant in its domestic market, we also consider the 6 Feb news that REA's CEO, Owen Wilson, intends to retire in 2H25. He is highly regarded in the industry and, crucially, was a key architect of the Rightmove bid," the broker said.

Despite the negative newsflow, Rightmove's shares are still trading at an 18% premium to the level prior to the REA bid in September.

Jefferies has a 495p target price on the stock, indicating 24% downside to the current price.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.